Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Teva Pharmaceutical Industries Limited < Previous 1 2 3 4 5 Next > AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, New Once-Daily Formulation of AUSTEDO®, Now Available in the U.S. May 15, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Reports First Quarter 2023 Financial Results and Reaffirms 2023 Non-GAAP Outlook May 10, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Shares Progress Toward Access to Medicines and Environmental Commitments, Meeting and Exceeding Several ESG Targets Ahead of Schedule May 09, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA U.S. Mental Health Access Program Expands Medicine Donation to Seven New States May 03, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults April 28, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Launch New Growth Strategy at Investor Day April 27, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023 April 14, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Complete Response Letter Received for AVT02 Biologics License Application April 13, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at the 2023 American Academy of Neurology Annual Meeting April 11, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva’s Digital Health Collaboration with Rimidi Expands to Include Respiratory Monitoring Program Integration with a Large U.S. Health System March 27, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps and Election of Early Settlement March 13, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid® (lenalidomide capsules), in the U.S. March 09, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Present at the Barclays Global Healthcare Conference March 07, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Announces Successful Upsize and Pricing of $2,490,000,000 (equivalent) Sustainability-Linked Senior Notes and the Increase of the Maximum Tender Amount of its Debt Tender Offer March 01, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Announces $2,250,000,000 Debt Tender Offers for Notes Due 2023-2026 February 27, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Announces Launch of $2,060,000,000 (Equivalent) Offering of Sustainability-Linked Senior Notes February 27, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Present New Data from CONNECT2 Study on its Digihaler® System at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting February 24, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Announces Publication of New Clinician Scale in Journal of Clinical Psychiatry to Assess the Impact of Tardive Dyskinesia on Patients’ Lives February 23, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO® (deutetrabenazine) Tablets February 17, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Reaches Agreement With Florida to Settle the State’s Price Fixing Claims February 09, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Reports Fourth Quarter and Full Year 2022 Financial Results February 08, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva’s Ambitious Climate Targets Externally Validated by the Science Based Targets initiative (SBTi) January 19, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and 2023 Financial Guidance at 8 a.m. ET on February 8, 2023 January 12, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Announces Nationwide Opioids Settlement to Move Forward After Receiving Broad Support from States January 09, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) January 06, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers ALVO TEVA Teva to Present at the 41st Annual J.P. Morgan Healthcare Conference January 03, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Finalizes Nationwide Opioid Settlement Terms November 22, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Announces Appointment of Richard Francis as President and CEO November 21, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Announces Unique Collaboration with Rimidi to Expand the Reach of its Respiratory Digital Health Platform November 14, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA Teva Announces Unique Collaboration with HealthSnap to Expand the Reach of its Respiratory Digital Health Platform November 14, 2022 From Teva Pharmaceutical Industries Limited Via Business Wire Tickers TEVA < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.